Chapter 50 Pain in Parkinson's disease

Pain coping strategies and their association with quality of life in people with Parkinson's disease: A cross-sectional study

OBJECTIVE

To develop multidimensional approaches for pain management, this study aimed to understand how PD patients cope with pain.

DESIGN

Cross-sectional, cohort study.

SETTING

Monocentric, inpatient, university hospital.

PARTICIPANTS

52 patients with Parkinson's disease (without dementia) analysed.

PRIMARY AND SECONDARY OUTCOME MEASURES

Motor function, nonmotor symptoms, health-related quality of life (QoL), and the Coping Strategies Questionnaire were assessed. Elastic net regularization and multivariate analysis of variance (MANOVA) were used to study the association among coping, clinical parameters, and QoL.

RESULTS

Most patients cope with pain through active cognitive (coping self-statements) and active behavioral strategies (increasing pain behaviors and increasing activity level). Active coping was associated with lower pain rating. Regarding QoL domains, active coping was associated with better physical functioning and better energy, whereas passive coping was associated with poorer emotional well-being. However, as demonstrated by MANOVA, the impact of coping factors (active and passive) on the Short Form 36 domains was negligible after correction for age, motor function, and depression.

CONCLUSION

Passive coping strategies are the most likely coping response of those with depressive symptoms, whereas active coping strategies are the most likely coping response to influence physical function. Although coping is associated with pain rating, the extent that pain coping responses can impact on QoL seems to be low.

Increased suicide risk and clinical correlates of suicide among patients with Parkinson's disease

INTRODUCTION

Parkinson's disease (PD) is a debilitating, neurodegenerative condition frequently complicated by psychiatric symptoms. Patients with PD may be at higher risk for suicide than the general population, but previous estimates are limited and conflicting. The aim of this study is to estimate the suicide rate based on the clinical case registry and to identify risk factors for suicide among patients diagnosed with PD.

METHODS

The target sample consisted of 4362 patients diagnosed with PD who were evaluated at a general hospital in Seoul, South Korea, from 1996 to 2012. The standardized mortality ratio for suicide among PD patients was estimated. In order to identify the clinical correlates of suicide, case-control study was conducted based on retrospective chart review. The 29 suicide cases (age: 62.3 ± 13.7 years; females: 34.5%) were matched with 116 non-suicide controls (age: 63.5 ± 9.2 years; females 56.9%) by the year of initial PD evaluation.

RESULTS

The SMR for suicide in PD patients was 1.99 (95% CI 1.33-2.85). Mean duration from time of initial diagnosis to suicide among cases was 6.1 ± 3.5 years. Case-control analysis revealed that male, initial extremity of motor symptom onset, history of depressive disorder, delusion, any psychiatric disorder, and higher L-dopa dosage were significantly associated with suicide among PD patients. Other PD-related variables such as UPDRS motor score were not significantly associated with death by suicide.

CONCLUSION

Suicide risk in PD patients is approximately 2 times higher than that in the general population. Psychiatric disorders, and also L-dopa medication need further attention with respect to suicide.

[Lumbar back pain in patients with Parkinson's disease]

BACKGROUND

Lumbar back pain is a frequent symptom in patients with advanced Parkinson's disease. We examined the effect of modification of the dopaminergic medication, x-ray-controlled lumbar spine injections and analgesics combined with physiotherapy.

METHODS

The data from 50 patients with Parkinson's disease and lumbar back pain were retrospectively analyzed. A structured L-dopa test was performed with all patients, whereby the pain intensity and mobility were monitored before and after the administration of L-dopa. Dopaminergic medication was adjusted in patients who reported either a reduction in pain intensity (> 20%) and/or an improvement of measured mobility and X-ray controlled lumbar spine injections were conducted in patients who reported persistent pain. Analgesics were introduced or dosages were raised in patients who had already received lumbar spine injections and continued to report pain. All patients participated in a daily physiotherapy program.

RESULTS

In the L-dopa test an improvement of mobility could be demonstrated in 40 patients and reduced pain intensity in 21 patients. In 37 patients with a positive L-dopa test the dopaminergic medication was adjusted. In 12 of these patients (24%) a decrease of pain intensity could be observed. Due to persisting back pain in 30 patients lumbar spine injections were conducted. Of these patients 17 (34%) had pain improvement. In 20 patients analgesics were applied and induced pain relief in 15 patients (30%). Overall 44 patients (88%) had an improvement in pain.

DISCUSSION

Even in cases of severe lumbar spine pathology adjustment of dopaminergic medication should be tested in all patients with Parkinson's disease and lumbar back pain. In patients with persistent pain facet joint injections as well as analgesics may be helpful and should be tested according to the predominant pain characteristics.

A cross-sectional study investigating clinical predictors and physical experiences of pain in Parkinson's disease

Pain is a non-motor symptom of Parkinson's disease (PD) that is often neglected due to its high prevalence in both the PD and the normal elderly population. The aims of this cross-sectional study were to establish the prevalence of pain, investigate its clinical predictors and analyze physical experiences of pain as described by PD patients. A total of 121 patients diagnosed with PD were included. The patients underwent a neurological examination and a structured interview and completed questionnaires focusing on clinical types and physical experiences of pain. Logistic regressions were used to analyze possible predictors. Pain was reported by 80 (66%) patients with a mean age at PD diagnosis of 67.26±11.43 years. The most common clinical types of pain experienced by the patients were dystonic pain (48%), paresthesia/neuropathic pain (36%) and musculoskeletal pain (28%). The PD patients described their physical experience of pain as aching (46%), a feeling of tension (18%), sharp pain (12%), deep pain (12%) and dull pain (11%). Patients with PD affecting the right side of the body were four times more likely to report pain on the right side of the body; however, no such relation was found for the left side of the body. A higher UPDRS-III scale score and longer PD duration reduced the likelihood of patients reporting dull pain. The presence of paresthesia/neuropathic pain was shown to decrease the likelihood of patients reporting sharp pain. No significant relationships were found between the magnitude of pain and gender, age at PD diagnosis, PD duration, UPDRS-III score, or Hoehn and Yahr stage of PD. Although 40% of the PD patients felt that medication had a (direct) effect on their pain, no relationship could be found between pain severity and PD medication.

Facilitated temporal summation of pain at spinal level in Parkinson's disease

BACKGROUND

Pain is one of the major nonmotor symptoms of Parkinson's disease. We hypothesized that Parkinson's disease patients could show an early diffuse abnormal processing of the nociceptive inputs also in the absence of clinical pain syndrome and that this could represent the physiopathological substrate to explain the high incidence of diffuse pain symptoms.

MATERIALS AND METHODS

We used the temporal summation threshold of the nociceptive withdrawal reflex and the related pain sensation to evaluate the facilitation in pain processing at spinal level. Fifteen (7 Women; 8 Men; mean age 63.0 ± 9.1) Parkinson's disease patients without clinical pain and 12 (6 Women, 6 Men; mean age 61.2 ± 4.2) healthy subjects were recruited. Parkinson's disease group has been subdivided into two subgroups, 7 early-stage Parkinson's disease patients with unilateral signs (Hoehn and Yahr stage 1) and 8 patients in a more advanced stage of the disease showing bilateral parkinsonian signs (Hoehn and Yahr stages 2 and 2.5), both "on" and "off" treatments with levodopa.

RESULTS

A significant facilitation in temporal summation of pain (reduced temporal summation threshold and increased painful sensation) was found in Parkinson's disease patients when compared with controls. This facilitation is more evident in Parkinson's disease with bilateral signs and on the side more affected in Parkinson's disease with unilateral signs. Levodopa administration failed to significantly modify the neurophysiological abnormalities; however, a slight improvement has been detected.

CONCLUSIONS

The increased gain in pain processing at spinal level in Parkinson's disease patients could be a consequence of the degenerative phenomena involving supraspinal projections implicated in the modulation of pain processing and could make Parkinson's disease patients more predisposed to develop a pain condition.